{"analyses":[{"ciLowerLimit":"15.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"32.20","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"23.65"},{"ciLowerLimit":"-0.11","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.16","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Event Free Rate","paramValue":"7.53"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.12","spread":"17.12","upperLimit":"28.00","value":"22.56"},{"groupId":"OG001","lowerLimit":"39.60","spread":"39.60","upperLimit":"52.81","value":"46.21"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.07","spread":"8.07","upperLimit":"17.52","value":"12.80"},{"groupId":"OG001","lowerLimit":"14.33","spread":"14.33","upperLimit":"26.32","value":"20.32"}]}],"title":"12 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"NUMBER","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Months 6 and 12","title":"Randomized Phase: Percentage of Participants With PFS Determined by Investigator at 6 Months and 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}